- Poster presentation
- Open Access
Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
Journal of the International AIDS Society volume 13, Article number: P30 (2010)
There are three classes of HIV-1 based on diversity of the viral envelope: M (major), O (outlying) and N (new). The M group is subclassified into nine major subtypes including A—D, F—H, J and K, as well as several recombinant forms. There is a growing need to evaluate antiretroviral (ARV) treatment in these diverse subtypes.
M06-802 was an open-label, global, 48-week phase III trial. 599 ARV-experienced, HIV-1-infected subjects were randomized 1:1 to receive LPV/r 800/200mg QD or 400/100mg BID with ≥2 investigator-selected nucleoside/nucleotide reverse transcriptase inhibitors. Classification of HIV-1 viruses by subtype was determined by analyzing sequences of the env gene for this post hoc analysis.
Of the 595 subjects with available sequence data, 386 (65%) were infected with subtype B, 121 (20%) were infected with subtype C, 88 (15%) were infected with another subtype. Subjects infected with subtype B were more likely to be male (75%), white (56%), and living in North America (N.A.) (52%), while subjects infected with subtype C were more likely to be female (56%), black (83%), and living outside of N.A. or Western Europe (W.E.) (99%). Subjects infected with other subtypes were more likely to be male (56%), white (88%) and living outside of N.A. or W.E. (82%). The proportion of subjects with subtype B responding to treatment at week 48 as analyzed using the FDA-TLOVR method (53%) was similar to that of subtype C subjects (57%, P=0.465) and non-B subtype subjects (55%, P=0.731) (Figure 1). The prevalence of moderate/severe treatment-related adverse events was similar across subtypes. There was a nonsignificant trend to more frequent emergence of new protease resistance mutations in subtype B (18%) vs. subtype C (8%, P=0.277) or non-B (7%, P=0.088) subjects; however, subtype B subjects were more likely to have previously been treated with PIs.
LPV/r demonstrated similar efficacy and safety among subjects infected with different HIV-1 subtypes.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Maroldo, L., Fredrick, L., Robinson-Morgan, K. et al. Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1. JIAS 13 (Suppl 4), P30 (2010). https://doi.org/10.1186/1758-2652-13-S4-P30
- Reverse Transcriptase
- Sequence Data
- Resistance Mutation
- Similar Efficacy
- Transcriptase Inhibitor